PCV34 COST-EFFECTIVENESS OF ATORVASTATIN PLUS AMLODIPINE VERSUS ATORVASTATIN PLUS ATENOLOL IN HYPERTENSIVE PATIENTS WITHOUT PREVIOUS CORONARY HEART DISEASE, NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS AND AT LEAST 3 CARDIOVASCULAR RISK FACTORS  by F Bobadilla, J et al.
model was adjusted. Diabetics and non-diabetics were analysed
separately. Data on effectiveness of 12 month treatment were
taken from RIO-Diabetes (overweight/obese patients with
T2DM) and RIO-Europe (overweight with co-morbidities/obese
patients, without T2DM), respectively. Cost data were derived
from published sources for the year 2006 using €2.39 as daily
costs of rimonabant. A time horizon of 40 years and a discount
rate of 3% were applied. Input model data were varied plus/
minus 20% performing sensitivity analyses. RESULTS: The
model shows that adding rimonabant to diet and exercise, in
patients with BMI 30 kg/m2, or BMI >27 kg/m2 and additional
risk factors leads to an increased life expectancy as well as an
improved quality of life. Costs per LYG were €12,322 (diabetics)
and €46,966 (non-diabetics). Costs per QALYG were €8,788
(diabetics) and €12,590 (non-diabetics). Considering the interna-
tionally utilized threshold of €50,000 per QALYG, the treatment
with rimonabant can be assessed as cost-effective. The robustness
of this result was substantiated through sensitivity analyses.
CONCLUSION: Based on the results of the Rainbow model,
treating patients with rimonabant in combination with diet and
exercise is associated with a beneﬁt in effectiveness at acceptable
costs from a SHI-perspective, compared to a modiﬁcation of
lifestyle alone.
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OBJECTIVES: To perform a cost-effectiveness analysis of irbe-
sartan for the management of nephropathy in patients with
hypertension, type-2 diabetes and microalbuminuria in the
Mexican scenario. METHODS: The treatment of patients was
simulated with early irbesartan, 300 mg daily (initiating in the
microalbuminuria stage) and late irbesartan (initiating in the
stage of manifest nephropathy). These strategies were compared
with a control, consisting of standard anti-hypertensive therapy.
The progression of microalbuminuria to nephropathy, increase
to the doubling of serum creatinine, end stage renal disease
(ESRD) to death, was simulated over a temporary horizon of 20
years, using a Markov model previously published and adapted
to the Mexican scenario. The transition probabilities were based
in the study named Irbesartan in Reduction of Micro-
albuminuria-2, and the study called Irbesartan in Diabetic
Nephropathy Trial, and local sources. The costs and clinical
outcomes were discounted to an annual rate of 3%, and the
perspective of the public health care institutions in Mexico.
RESULTS: With early irbesartan there was a gain of 539.1 years
of life per 1000 treated patients, and with late irbesartan there
was a gain of 131.1, both compared to control. After 20 years
of treatment, early irbesartan prevented 87 cases of ESRD per
1000 patients treated, and late irbesartan prevented 54, both
compared to control. The cost per life-year gained with early
irbesartan was €22,998.93 and the cost per year free from
ESRD with late irbesartan was €11,503.94. The sensitivity
analysis showed that therapy with irbesartan is still cost-
effective compared to conventional antihypertensive treatment
after modifying various plausible assumptions. CONCLUSION:
The addition of irbesartan to conventional antihypertensive
therapy demonstrated an improvement in life expectancy and
reduction in the years with ESRD. It represented a cost-effective
option compared to control, which means greater efﬁciency in
the treatment of hypertension patients with type-2 diabetes and
microalbuminuria in Mexico.
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OBJECTIVES: Acute decompensated heart failure (AHF) is life-
threatening and a frequent cause of hospitalization for older
persons. The SURVIVE randomized controlled trial compared
levosimendan (levo) versus dobutamine (dob) with 180-day
mortality as primary endpoint. All-cause mortality at 31 days
was levo 12% and dob 14% (hazard ratio 0.85, p = 0.29) with
a similar differential at 180 days (HR 0.91, p = 0.40). Presented
here is the SURVIVE economic analysis. METHODS: SURVIVE
was conducted in Russia, Poland, France, Israel, Finland, UK,
Latvia, Germany, and Austria. Enrolled patients (N = 1327)
required IV inotropic support after insufﬁcient response to IV
diuretics or vasodilators. Case report forms (CRFs) documented
study drug administration, inpatient days (ICU, routine care),
procedures (e.g., PTCA, CABG, ICD), and safety data, during
initial admission. CRFs also described subsequent admissions
during follow-up. Hospital cost was calculated according to
length of day and procedures. Source of cost data was national
hospital payment schedules for France, Germany, and UK. Cost
for levo was not included in base case analysis. Cost-
effectiveness analysis used average market price for levo with
post-trial survival projected per published AHF methodology.
RESULTS: Length of stay (days) during initial admission was
identical (levo 14.4, dob 14.5, p = 0.96). During follow-up
similar patterns were observed for number of hospital admis-
sions (levo 0.7, dob 0.9, p = 0.25) and total hospital days (levo
11.5, dob 12.4, p = 0.46). Mean cost of initial hospital admis-
sion was similar (levo €5060, dob €4945, p = 0.91) as was total
hospital cost for the complete trial episode (levo €5471, dob
€5273, p = 0.93). Incremental cost per life year gained for levo
relative to dob was less than €27,000 with greater than 50%
likelihood. CONCLUSION: In SURVIVE hospital resource use
and costs were similar for levo and dob. Based on the survival
difference, levo is cost-effective relative to dob using accepted
benchmarks.
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OBJECTIVES: To assess the cost per quality-adjusted-life-year
(QALY) of Atorvastatin 10 mg (ATV) + Amlodipine 5/10 mg
(AML) compared with Atenolol 10 mg (ATE) + ATV, in hyper-
tensive patients with no history of coronary heart disease (CHD)
with normal to mildly elevated cholesterol and with at least 3
Abstracts A415
additional cardiovascular-risk-factors (ASCOT-LLA patients).
ASCOT-BPLA study compared 2 different antihypertensive
strategies (ATE+/-Bendroﬂumethiazide+/-Doxazosin) and AML
(+/-Perindopril+/-Doxazosin) to reduce cardiovascular events
in 19,257 hypertensive patients. AML demonstrated less all
cause mortality than ATE (p = 0.025). A sub-study (ASCOT-
LLA) comparing ATV to Placebo (PCB) in patients with
250 mg/dL was carried out. The ASCOT-LLA was early inter-
rupted because of a signiﬁcant reduction in the primary end-
point in favour of Atorvastatin. A factorial analysis of ASCOT-
LLA (ATV + AML; PBO + AML; ATV + ATE; PBO-ATE)
demonstrated a 53% relative risk reduction of ATV + AML
versus PBO + AML (p < 0.0001); and of 39% for ATV + AML
versus ATV + ATE (p = 0.016). METHODS: Two hypothetical
cohorts of ASCOT-LLA like patients were simulated for a 25
years time horizon under the perspective of the National Health
System, by a Markov model. Spanish costs (€2005) of ATV,
AML, ATE, Peridonpril and Bendroﬂumethiazide were taken
into account. Effects were based on results of the ASCOT 2x2
analysis: ATV + AML versus ATV + ATE. Results are expressed
as incremental cost-effectiveness ratio (ICER) per QALY. Costs
and effectiveness outcomes were discounted at a rate of 3%
and 5% per year, respectively. RESULTS: The basecase analysis
demonstrates that ATV + AML strategy is a more effective
alternative with an acceptable increase in costs: ICER
of ATV + AML was 17.334€ per QALY. CONCLUSION:
Atorvastatin + Amlodipine is a cost-effective strategy when
compared with Atorvastatin + Atenolol for the treatment of
hypertensive patients with no prior history of cardiovascular
disease, normal to mildly elevated cholesterol levels and with
at least 3 additional cardiovascular-risk-factors, being under
the threshold of 30.000€ per QALY usually accepted in our
environment.
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OBJECTIVES: To evaluate clinical and economic beneﬁt of
Drug Eluting Stents (DES) in comparison with Bare-Metal
Stents (BMS) and surgical treatment with coronary artery
bypass graft (CABG) for Sicily Regional Government.
METHODS: Cost-effectiveness analysis was carried out by two
decision models: patients treated with DES vs. BMS. Cost was
carried out from the point of view of the SSR (Servizio Sani-
tario Regionale, Regional Health Service). RESULTS: The use
of DES generated unitary differential savings of €9,003, after
9 months of follow-up, and total differential savings of
€4,114,371. The use of DES on patients destined to BMS gave
average unitary differential savings of €1,075, after 9 months of
follow-up, and average total differential savings of €927,875.
The use of DES instead of BMS and CABG allowed SSR to
make average differential savings of €3,735 per successful case.
A total of €2,476 represent the refund threshold value of DES,
setting to zero the SSR average differential savings for patients
treated with DES who would otherwise have been treated with
BMS. CONCLUSION: Results of the proposed models, tested
with sensitivity analysis, demonstrate the use of DES to be jus-
tiﬁed; moreover, these results could positively inﬂuence the atti-
tude of the SSR towards these new therapeutic strategies, which
are an improvement on standard therapies, both from a clinical
and a ﬁnancial standpoint.
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OBJECTIVES: Familial hypercholesterolemia (FH) is character-
ized by elevated LDL-Cholesterol and premature cardiovascular
disease. To evaluate the efﬁciency of preventive strategies, a
cost-effectiveness model was developed: treatment in real clinical
practice, different atorvastatin dosage in monotherapy 40 mg
(A40) or 80 mg (A80) and atorvastatin combined with Ezetimebe
10 mg (A40 + E10, A80 + E10). METHODS: A Markov model
under National Health System perspective and with a timeframe
of all life expectancy was developed. Spanish life tables (2002)
were modiﬁed with standard mortality rate for FH population
(1.59; IC-95% = 1.07–2.26) to convert the reduction of mortal-
ity into life years gained (LYG). Treatment effectiveness was
transformed in CV mortality reduction by using risk reduction
based on Framingham risk score. Statins, clinical management
and pharmacological costs were taken into account (Spanish
costs €2005). Costs and effectiveness were discounted at a rate of
6% and 3% per year, respectively. RESULTS: 1) Basecase sce-
nario (BS), based on Spanish FH database would represent 1.97
LYG per patient in comparison to no treatment, costs due statins
were €5.321, other management costs (MC) €23.389 and total
costs (TOC) €28710; 2) A40: 2.59 LYG, MC was reduced 4.5%
in comparison to BS; TOC were €30.569; 3)A80: 2.75 LYG,
reduction of MC:6.4%, and TOC: €30.133; 4)A40 + E10: 3.38
LYG, reduction of MC:14.3% and TOC: €36.104; and
5)A80 + E10: 3.62 LYG, reduction of CM: 17.6% and TOC:
€35.317. Management strategies from more to less efﬁcient incre-
mental cost-effectiveness rate (ICER) per LYG in comparison to
BS were: a) A80: €1.821; b) A40: €3.012; and c) A80 + E10:
€4.021; and d) A40 + E10: €5.250. CONCLUSION: Manage-
ment of FH with atorvastatin-based treatment is an efﬁcient
strategy: Atorvastatin 80 mg in monotherapy is the most efﬁ-
cient. If LDL therapeutic goals with Atorvastatin 80 mg are not
achieved, the concomitant use of Ezetimibe can give an addi-
tional effect with an acceptable incremental cost.
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OBJECTIVES: To evaluate the cost-effectiveness of atorvasta-
tin, rosuvastatin, and simvastatin in reducing LDL-cholesterol
(LDL-C) and in treatment of patients with high risk of fatal
cardiovascular disease to meet the European LDL-C target level
of 2.5 mmol/l. METHODS: The efﬁcacy of statins in terms of
mean percent reduction in LDL-C was determined by literature
review and Bayesian random effects meta-analysis. A simula-
tion model was created to evaluate the proportion of patients
treated to the LDL-C target (PTT) level of 2.5 mmol/l. The
uncertainty related to the independent variables was modeled
with Bayesian MCMC-simulation with the use of WinBUGS
software. The measures of cost-effectiveness were calculated by
annual medicine costs per PTT and by incremental cost-
effectiveness ratios (ICERs). The annual medicine costs were
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